HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hannah Daniel

Having recently joined the team in 2022, Hannah Daniel is a consumer health reporter for Pharma Intelligence’s Health, Beauty, and Wellness publication.

Latest From Hannah Daniel

Bragg Live Wants Consumers To Know Efficacy Differs Among Apple Cider Vinegar Formats

Bragg Live says its survey highlights misconceptions consumers have concerning health benefits and efficacy of different delivery formats of apple cider vinegar.

Dietary Supplements Market Intelligence

House Appropriators Say Infant Formula Shortage Signals Restructuring Needed At US FDA

"Many of the problems facing [the FDA] can be solved through strong leadership rather than more money,” says Rep. Andy Harris during Appropriations subcommittee hearing, Committee Chairwoman Rosa DeLauro continues her criticism of FDA's regulation of industries under its oversight, saying a "structural problem" caused infant formula shortage.    

FDA Safety

Over The Counter 24 May 2022: US OTC Monograph Reform And A 'Faster Moving FDA’ With CHPA’s Barbara Kochanowski and David Spangler

In this episode, HBW Insight speaks to Barbara Kochanowski and David Spangler of the US Consumer Healthcare Products Association about OTC monograph reform. The OTC monograph program was reimagined as a part of the 2020 CARES act passed in the early stages of the pandemic. While the changes were designed to streamline and modernize the program, results have been slow with the FDA's attention focused on tackling COVID-19. But as the agency hires more staff, Spangler says he expects to see a "faster moving FDA" in the next three years. Spangler and Kochanowski also discuss the efficacy of the monograph reforms and how CHPA has helped educate its members about the changes.

OTC Drugs United States

Urged By US FDA To Boost Infant Formula Supply, Additional Providers Still Must Wait For Approval

Patricia Hansen, CFSAN’s Office of Nutrition and Food Labeling deputy director and John Verbeten, deputy director for Import Operations Enforcement laid out the FDA's new enforcement guidance, and urged businesses with available formula to wait for approval before distributing formula in the US.

FDA Guidance Documents

House Appropriators Sound Off During FDA Hearing About Formula, More Consumer Health Issues

Before Agriculture/FDA subcommittee about FY2023 budget, Commissioner Robert Califf says FDA needs more resources to address unlisted fragrances in menstrual products and doesn’t have good regulatory options for hemp and kratom. His formula emergency comments leave members frustrated.

FDA Policy

Hemp Roundtable Says Safety Study Data Should Convince Congress On Lawful CBD Use

Study of 1,061 subjects showed oral CBD has robust safety profile, addressing FDA’s safety concerns and providing evidence to convince agency to take action on CBD regulation, say trade groups.

Legislation Cannabidiol CBD
See All